All Clinical Trials

Clinical Trial NCT03126916

ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

  • ClinicalTrials.gov ID: NCT03126916
  • Recruiting participants (Starts Jul. 2, 2018)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: TANYA CARENS WATT

summary

The current phase 3 trial seeks to improve the event-free survival (eFS) for children with high-risk neuroblastoma through early integration of promising novel targeted therapies: targeted radiopharmaceutical therapy with 131i-MiBG or the aLK inhibitor, crizotinib. after enrollment, patients will receive one cycle of induction chemotherapy. Subsequent therapy will be based upon MiBG avidity and aLK status.

objective

Primary aims - To determine in the context of a randomized trial whether the eFS of patients with newly diagnosed high-risk nBL is improved with the addition of 131i-MiBG during induction, prior to tandem autologous stem cell transplantation (aSCT).

If you are interested in this clinical trial, please contact Beverly Kleiber on the Children’s Health Research Team.Call 214-645-6980Email